Dompé has enrolled the first patient in a phase 2b clinical trial of its recombinant human nerve growth factor eye solution for the treatment of dry eye disease, according to a press release. NGF0118 study will evaluate the safety and efficacy of rhNGF in approximately 300 moderate to severe dry eye patients at 11 U.S. sites, the release said.
"The effects of currently available treatments for chronic dry eye disease mostly address only inflammation and wear off soon after discontinuing therapy. Our researchers have decades of understanding of the mechanism (Read more...)
Uncategorized